2024
High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn’s Disease
Ebach D, Jester T, Galanko J, Firestine A, Ammoury R, Cabrera J, Bass J, Minar P, Olano K, Margolis P, Sandberg K, Linnville T, Kaplan J, Pitch L, Steiner S, Bass D, Moses J, Adler J, Gulati A, Wali P, Pashankar D, Ivanova A, Herfarth H, Wohl D, Benkov K, Strople J, Sullivan J, Tung J, Molle-Rios Z, Saeed S, Bousvaros A, Kappelman M. High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn’s Disease. The American Journal Of Gastroenterology 2024, 119: 1110-1116. PMID: 38445644, PMCID: PMC11150092, DOI: 10.14309/ajg.0000000000002741.Peer-Reviewed Original ResearchHigher Body Mass IndexNormal body mass indexPediatric Crohn's diseaseBody mass indexAnti-TNF levelsInfliximab initiationTrough levelsTreatment failureObese patientsMass indexTime-to-treatment failureCrohn's diseaseResponse to anti-TNF therapyAssociated with treatment failureMonotherapy to combination therapyBody mass index groupsBody mass index categoriesPrescribed anti-TNFProactive drug monitoringAdalimumab-treated patientsDrug trough levelsAnti-TNF treatmentAnti-TNF therapyInfliximab trough levelsWeight-based dosingUse of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians
Wiseman A, Alhamad T, Alloway R, Concepcion B, Cooper M, Formica R, Klein C, Kumar V, Leca N, Shihab F, Taber D, Mulnick S, Bushnell D, Hadi M, Bunnapradist S. Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians. Annals Of Transplantation 2024, 29: e943498-1-e943498-13. PMID: 38526543, PMCID: PMC10944009, DOI: 10.12659/aot.943498.Peer-Reviewed Original ResearchConceptsLCP-tacrolimusImmediate-release tacrolimusKidney transplantationFirst-line optionKidney transplant recipientsRandomized clinical trialsDe novo settingTacrolimus formulationReview available dataEvidence-based recommendationsTrough levelsOnce-DailyTransplant recipientsClinical decision-makingOptimal doseClinical trialsExpert cliniciansConsensus statementTransplant expertsStrength of evidenceClinical practiceKidneyTacrolimusDe novoDelphi consensus surveyUstekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease
Petrov J, Fine S, Alzahrani R, Mohamed G, Al-Bawardy B. Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease. Journal Of Clinical Gastroenterology 2024, 59: 77-81. PMID: 38300529, DOI: 10.1097/mcg.0000000000001978.Peer-Reviewed Original ResearchArea under the curveInflammatory bowel diseaseEndoscopic healingTrough levelsBowel diseaseAssociated with favorable outcomesUstekinumab trough levelsHighest area under the curveCohort of patientsTherapeutic drug monitoringClinical remissionCombination therapyMedian ageCRP normalizationRetrospective studyDrug levelsFavorable outcomeUstekinumabDrug monitoringPrimary outcomeSecondary outcomesCRPPatientsOutcomesHealing
2023
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
Pratz K, Cherry M, Altman J, Cooper B, Podoltsev N, Cruz J, Lin T, Schiller G, Jurcic J, Asch A, Wu R, Hill J, Gill S, James A, Rich E, Hasabou N, Perl A, Levis M. Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. Journal Of Clinical Oncology 2023, 41: 4236-4246. PMID: 37379495, DOI: 10.1200/jco.22.02721.Peer-Reviewed Original ResearchConceptsPhase Ib studyMaintenance therapyConsolidation chemotherapyDose escalationFLT3 inhibitorsIb studyHigh-dose cytarabine consolidationMedian overall survival timeSingle-agent maintenance therapyComplete response rateHigher trough levelsOverall survival timeCytarabine consolidationChemotherapy regimenDose expansionAdult patientsIntensive inductionTrough levelsCount recoveryMedian timeRandomized trialsInduction cyclesSurvival timeDay 1Response rate
2021
Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience
Ramos G, Al-Bawardy B, Neto M, Bledsoe A, Quinn K, Heron V, Willrich M, Johnson A, Chedid V, Coelho-Prabhu N, Kisiel J, Papadakis K, Pardi D, Kane S, Tremaine W, Raffals L, Bruining D, Faubion W, Harmsen W, Loftus E. Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. Crohn's & Colitis 360 2021, 3: otab019. PMID: 36776673, PMCID: PMC9802288, DOI: 10.1093/crocol/otab019.Peer-Reviewed Original ResearchRadiologic responseClinical responseCertolizumab pegolMucosal healingCrohn's diseaseRadiologic healingCD patientsTrough levelsPositive antibody levelsSingle-center experienceCD outcomesAntibody levelsClinical managementOdds ratioCTL levelsHigher oddsRetrospective evaluationPatientsBiochemical responsesClinical practiceQuartile analysisAntibodiesCharacteristic curveOutcomesDisease
2020
Acute kidney injury in renal transplant recipients undergoing cardiac surgery
Hundemer G, Srivastava A, Jacob K, Krishnasamudram N, Ahmed S, Boerger E, Sharma S, Pokharel K, Hirji S, Pelletier M, Safa K, Kulvichit W, Kellum J, Riella L, Leaf D. Acute kidney injury in renal transplant recipients undergoing cardiac surgery. Nephrology Dialysis Transplantation 2020, 36: 185-196. PMID: 32892219, PMCID: PMC7771983, DOI: 10.1093/ndt/gfaa063.Peer-Reviewed Original ResearchConceptsRenal transplant recipientsAcute kidney injuryNon-RTRsCardiac surgeryCalcineurin inhibitorsRisk factorsTransplant recipientsKidney injuryType of cardiac surgeryKidney diseaseRates of acute kidney injuryRisk of acute kidney injuryDeceased donorsGlobal Outcomes criteriaLiving donorsRetrospective cohort studyAssociated with higher ratesChronic kidney diseaseTrough levelsClinical characteristicsAcademic medical centerCohort studySurgeryHigh riskMedical CenterUpdates in periprocedural management of direct oral anticoagulants.
Tao J, Oprea AD. Updates in periprocedural management of direct oral anticoagulants. Current Opinion In Anaesthesiology 2020, 33: 423-431. PMID: 32371643, DOI: 10.1097/aco.0000000000000873.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsPeriprocedural managementOral anticoagulantsPrevalence of patientsDrug interruptionTrough levelsComplete clearanceProcedural riskPartial clearanceClinical riskAmerican CollegeElectrophysiology proceduresFavorable pharmacokineticsQuick onsetAnticoagulantsRiskClearanceDrugsReview detailsBleedingMedicationsManagementPatientsAntithromboticsAnesthesiologists
2019
Tacrolimus and Indomethacin Are Safe and Effective at Reducing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography in Patients Who Have Undergone Liver Transplantation
Thiruvengadam NR, Forde KA, Chandrasekhara V, Ahmad NA, Ginsberg GG, Khungar V, Kochman ML. Tacrolimus and Indomethacin Are Safe and Effective at Reducing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography in Patients Who Have Undergone Liver Transplantation. Clinical Gastroenterology And Hepatology 2019, 18: 1224-1232.e1. PMID: 31622734, DOI: 10.1016/j.cgh.2019.10.014.Peer-Reviewed Original ResearchConceptsEndoscopic retrograde cholangiopancreatographyRisk of PEPDevelopment of PEPLiver transplantationTrough levelsBiliary complicationsIndomethacin useRectal indomethacinRetrospective studyRetrograde cholangiopancreatographyERCP proceduresOdds ratioMixed-effects multivariable logistic regressionEffectiveness of tacrolimusIncidence of PEPTacrolimus trough levelsCommon adverse eventsChronic kidney diseaseGlomerular filtration rateMultivariable logistic regressionRate of pancreatitisAddition of indomethacinChronic rejectionSevere PEPStable doseDistinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease
Park S, Al-Bawardy B, Aniwan S, Kane S, Coelho-Prabhu N, Papadakis K, Kisiel J, Bruining D, Faubion W, Raffals L, Pardi D, Tremaine W, Stephens M, Tung J, Khanna S, Willrich M, Loftus E. Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2019, 1: otz047. DOI: 10.1093/crocol/otz047.Peer-Reviewed Original ResearchAdalimumab trough levelsRadiologic responseDisease activityTrough levelsReferral center-based cohortInflammatory bowel disease patientsRadiologic disease activityBowel disease patientsInflammatory bowel diseaseC-reactive proteinDifferent therapeutic outcomesHigher cutoff levelsBowel diseaseDisease patientsCutoff levelTherapeutic outcomesCutoff valuePatientsCohortIBDLevelsDiseaseResponse
2018
Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease
Al-Bawardy B, Ramos GP, Willrich MAV, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ, Loftus EV. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018, 25: 580-586. PMID: 30165638, DOI: 10.1093/ibd/izy272.Peer-Reviewed Original ResearchConceptsMedian vedolizumab trough levelsVedolizumab trough levelsC-reactive proteinInflammatory bowel diseaseNormal C-reactive proteinMucosal healingCrohn's diseaseUC patientsBowel diseaseTrough levelsUlcerative colitisClinical managementFourth of patientsTrough level measurementMayo endoscopic scoreCross-sectional studyHigh CRP patientsBiomarker normalizationIBD patientsClinical remissionCRP patientsEndoscopic scoreMucosal ulcersDetectable antibodiesBACKGROUND/Kidney Dysfunction After Vascularized Composite Allotransplantation
Krezdorn N, Tasigiorgos S, Wo L, Lopdrup R, Turk M, Kiwanuka H, Ahmed S, Petruzzo P, Bueno E, Pomahac B, Riella L. Kidney Dysfunction After Vascularized Composite Allotransplantation. Transplantation Direct 2018, 4: e362. PMID: 30046652, PMCID: PMC6056276, DOI: 10.1097/txd.0000000000000795.Peer-Reviewed Original ResearchGlomerular filtration rateKidney dysfunctionCreatinine levelsTrough levelsRisk factorsCalcineurin inhibitor trough levelsNonrenal solid organ transplantsLong-term patient outcomesFirst year posttransplantSuccessful midterm outcomesRenal risk factorsSolid organ transplantsAlternative immunosuppressive agentsComposite tissue transplantationAcute rejectionVCA patientsYear posttransplantMidterm outcomesRenal dysfunctionIR patientsKidney complicationsRenal functionMajor complicationsImmunosuppressive agentsKidney parameters
2017
Randomized, double‐blind, placebo‐controlled dose‐finding study of the dipeptidyl peptidase‐4 inhibitor linagliptin in pediatric patients with type 2 diabetes
Tamborlane WV, Laffel LM, Weill J, Gordat M, Neubacher D, Retlich S, Hettema W, Hoesl CE, Kaspers S, Marquard J. Randomized, double‐blind, placebo‐controlled dose‐finding study of the dipeptidyl peptidase‐4 inhibitor linagliptin in pediatric patients with type 2 diabetes. Pediatric Diabetes 2017, 19: 640-648. PMID: 29171139, DOI: 10.1111/pedi.12616.Peer-Reviewed Original ResearchConceptsDPP-4 inhibitionDipeptidyl peptidase-4 inhibitor linagliptinType 2 diabetesInhibitor linagliptinAdult patientsPediatric patientsPlacebo-controlled dose-finding studyDrug-related adverse eventsPrimary efficacy endpointParallel-group studyWeeks of treatmentDose-finding studyDose-dependent reductionEfficacy endpointMean HbA1cAdverse eventsFPG levelsTrough levelsClinical efficacySafety profilePlasma glucosePharmacodynamic endpointsStudy populationPatientsLinagliptin
2015
Increased phosphorylation of the renal Na+-Cl− cotransporter in male kidney transplant recipient patients with hypertension: a prospective cohort
Rojas-Vega L, Jiménez-Vega A, Bazúa-Valenti S, Arroyo-Garza I, Jiménez J, Gómez-Ocádiz R, Carrillo-Pérez D, Moreno E, Morales-Buenrostro L, Alberú J, Gamba G. Increased phosphorylation of the renal Na+-Cl− cotransporter in male kidney transplant recipient patients with hypertension: a prospective cohort. American Journal Of Physiology. Renal Physiology 2015, 309: f836-f842. PMID: 26336164, DOI: 10.1152/ajprenal.00326.2015.Peer-Reviewed Original ResearchConceptsHypertensive patientsUrinary exosomesPosttransplant hypertensionHistory of acute rejectionKidney transplant recipient patientsTacrolimus trough blood levelsPatients treated with tacrolimusAmbulatory 24-h blood pressure monitoringAdult kidney transplant recipientsTacrolimus-induced hypertensionTacrolimus trough levelsTrough blood levelsNa+-Cl- cotransporterTransplant recipient patientsKidney transplant recipientsDevelopment of hypertensionProspective cohort studyBlood pressure monitoringImmunosuppressive therapyNCC expressionHigh blood pressureTrough levelsAcute rejectionKidney allograftsTransplant recipients
2013
Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients
Heavner MS, Tichy EM, Yazdi M, Formica RN, Kulkarni S, Emre S. Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients. American Journal Of Health-System Pharmacy 2013, 70: 1507-1512. PMID: 23943182, DOI: 10.2146/ajhp120783.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsBrand-name tacrolimusTrough tacrolimus levelsTransitions of careTransplant recipientsAcute rejectionTacrolimus levelsTacrolimus dosageHospital admissionBiopsy-proven acute rejectionSingle-center observational studyTacrolimus trough levelsMonths of dischargePercentage of patientsMeeting study criteriaPeriod of careGeneric tacrolimusKidney transplantTrough concentrationsTrough levelsClinical outcomesDosage adjustmentGeneric formulationStudy criteriaObservational studyA phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.
Kristeleit R, Shapiro G, LoRusso P, Infante J, Flynn M, Patel M, Tolaney S, Hilton J, Calvert A, Giordano H, Isaacson J, Borrow J, Allen A, Jaw-Tsai S, Burris H. A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors. Journal Of Clinical Oncology 2013, 31: 2585-2585. DOI: 10.1200/jco.2013.31.15_suppl.2585.Peer-Reviewed Original ResearchAdvanced solid tumorsOral rucaparibStable diseaseTrough levelsSolid tumorsIntra-patient dose escalationOverall disease control rateTreatment-related adverse eventsOral small-molecule inhibitorDose-proportional PKDurable stable diseaseLow interpatient variabilityPhase 2 doseDisease control rateDose-escalation designDose cohortsBID dosingAdverse eventsObjective responsePK assessmentDose escalationEscalation designControl rateQD dosingStandard treatmentGenetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation
Chakkera HA, Chang Y, Bodner JK, Behmen S, Heilman RL, Reddy KS, Mulligan DC, Moss AA, Khamash H, Katariya N, Hewitt WR, Pitta TL, Frassetto LA. Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation. Transplantation Proceedings 2013, 45: 137-141. PMID: 23375287, DOI: 10.1016/j.transproceed.2012.10.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Cohort StudiesFemaleGenetic VariationHumansImmunosuppressive AgentsIndians, North AmericanKidney Failure, ChronicKidney TransplantationMaleMiddle AgedPharmacogeneticsPolymorphism, Single NucleotideTacrolimusTime FactorsConceptsKidney transplant recipientsTrough levelsTacrolimus dosingTransplant recipientsSingle nucleotide polymorphismsDaily tacrolimus doseLower tacrolimus dosesTacrolimus pharmacokinetic parametersTacrolimus trough levelsCaucasian kidney transplant recipientsStable dosesTacrolimus doseKidney transplantationTacrolimus dosesTacrolimus pharmacokineticsMonths posttransplantationOral clearanceTacrolimus clearanceDrug eliminationPharmacokinetic parametersVariant single nucleotide polymorphismsTacrolimusDrug metabolismPharmacokinetic studyLow dosage
2012
A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation.
Abu-Elmagd K, Costa G, Bond G, Soltys K, Martin L, Koritsky D, Cunha-Melo J, Sogawa H, Irish W, Tzakis A, Mazariegos G. A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation. Clinical Transplants 2012, 155-66. PMID: 23721018.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlemtuzumabAnimalsAntibodies, Monoclonal, HumanizedAntilymphocyte SerumAntineoplastic AgentsFemaleGraft RejectionGraft SurvivalGraft vs Host DiseaseHumansImmunosuppressive AgentsIncidenceInfectionsIntestinesMaleMiddle AgedMorbidityPancreas TransplantationRabbitsStomachTransplantation, HomologousYoung AdultConceptsDose of rabbit antithymocyte globulinDe novo malignanciesRabbit antithymocyte globulinTacrolimus trough levelsLong-term immunosuppressionRe-transplantation rateLife-threatening infectionsLong-term survivalAntithymocyte globulinTacrolimus monotherapyAdrenal insufficiencyAllograft acceptanceRecipient pretreatmentTrough levelsImmunosuppressive strategiesSteroid-freeGraft lossSingle-doseAcute/chronic rejectionRe-transplantationGraft survivalMultivisceral transplantationSingle doseSerum sicknessAlemtuzumab pretreatment
2011
Predictive factors for ciclosporin-associated nephrotoxicity in children with minimal change nephrotic syndrome
Kim J, Park J, Yoon S, Lim B, Jeong H, Lee J, Kim P, Shin J. Predictive factors for ciclosporin-associated nephrotoxicity in children with minimal change nephrotic syndrome. Journal Of Clinical Pathology 2011, 64: 516. PMID: 21441261, DOI: 10.1136/jclinpath-2011-200005.Peer-Reviewed Original ResearchConceptsCyA trough levelsTrough levelsGroup IIGroup ICyA therapyNephrotic syndromePredictive factorsDuration of CyA therapyRisk factorsTreated with CyADose of CyAResponse to steroidsIndependent risk factorMultiple logistic regression analysisSignificant risk factorsSerial renal biopsiesLogistic regression analysisCreatinine clearanceRelapse rateRenal biopsyLaboratory findingsDrug levelsCyAMCNSSteroids
2000
Interaction of Methadone with Didanosine and Stavudine
Rainey P, Friedland G, McCanceKatz E, Andrews L, Mitchell S, Charles C, Jatlow P. Interaction of Methadone with Didanosine and Stavudine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 241-248. PMID: 10969348, DOI: 10.1097/00126334-200007010-00007.Peer-Reviewed Original ResearchConceptsD4TMethadone therapyMore nucleoside analoguesStable methadone therapyActive antiretroviral therapyEffects of methadonePeak drug concentrationInjection drug usersInteraction of methadoneOpiate-dependent injection drug usersCurrent HAART regimensTime-concentration curveExtrapolated AUCMethadone dispositionAntiretroviral therapyHAART regimensDosing intervalTrough levelsMethadone treatmentHistorical controlsLarge dosesStudy subjectsDrug usersMethadoneDrug concentrationsInteraction of Methadone with Didanosine and Stavudine
Rainey P, Friedland G, McCance-Katz E, Andrews L, Mitchell S, Charles C, Jatlow P. Interaction of Methadone with Didanosine and Stavudine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 241-248. DOI: 10.1097/00042560-200007010-00008.Peer-Reviewed Original ResearchConceptsD4TMethadone therapyMore nucleoside analoguesStable methadone therapyActive antiretroviral therapyEffects of methadonePeak drug concentrationInjection drug usersInteraction of methadoneOpiate-dependent injection drug usersCurrent HAART regimensTime-concentration curveExtrapolated AUCMethadone dispositionAntiretroviral therapyHAART regimensDosing intervalTrough levelsMethadone treatmentHistorical controlsLarge dosesStudy subjectsDrug usersMethadoneDrug concentrations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply